Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia

-  Cytovant licenses East Asian rights for a research-stage T-cell receptor (TCR) against tumor antigen NY-ESO-1 as well as rights for Medigene's dendritic cell (DC) vaccine for the treatment of patients acrossEast Asia -  Cytovant and Medigene to collaborate on research and discovery of two add...